IN2015DN02233A - - Google Patents

Info

Publication number
IN2015DN02233A
IN2015DN02233A IN2233DEN2015A IN2015DN02233A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A IN 2233DEN2015 A IN2233DEN2015 A IN 2233DEN2015A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A
Authority
IN
India
Prior art keywords
dendrimer
macromolecule
eye
salt
generations
Prior art date
Application number
Other languages
English (en)
Inventor
Jacinth Kincaid; Fairley
Colin Paul; Barrett
Jeremy Robert Arthur; Paull
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2015DN02233A publication Critical patent/IN2015DN02233A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/795Polymers containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2233DEN2015 2012-09-13 2013-09-13 IN2015DN02233A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700714P 2012-09-13 2012-09-13
PCT/US2013/059810 WO2014043576A1 (en) 2012-09-13 2013-09-13 Method of treatment or prophylaxis of infections of the eye

Publications (1)

Publication Number Publication Date
IN2015DN02233A true IN2015DN02233A (enrdf_load_stackoverflow) 2015-08-21

Family

ID=50278734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2233DEN2015 IN2015DN02233A (enrdf_load_stackoverflow) 2012-09-13 2013-09-13

Country Status (9)

Country Link
US (2) US10149885B2 (enrdf_load_stackoverflow)
EP (1) EP2895161B1 (enrdf_load_stackoverflow)
JP (2) JP6419701B2 (enrdf_load_stackoverflow)
CN (2) CN108452316B (enrdf_load_stackoverflow)
CA (1) CA2884897C (enrdf_load_stackoverflow)
DK (1) DK2895161T3 (enrdf_load_stackoverflow)
ES (1) ES2633778T3 (enrdf_load_stackoverflow)
IN (1) IN2015DN02233A (enrdf_load_stackoverflow)
WO (1) WO2014043576A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
RU2667118C1 (ru) * 2017-11-15 2018-09-14 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Универсальное средство в виде мази для комплексного лечения глазных болезней животных и способ его получения
CN110664757B (zh) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
CN116056714A (zh) * 2020-04-15 2023-05-02 星法马有限公司 预防冠状病毒及/或呼吸道融合病毒感染的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM623994A0 (en) 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
JP2002520359A (ja) 1998-07-14 2002-07-09 ファルマシア・アンド・アップジョン・カンパニー 眼の感染症を治療するためのオキサゾリジノン
AUPP584298A0 (en) 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
AUPR412801A0 (en) 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
WO2005099715A2 (en) 2004-04-08 2005-10-27 Retmed Pty Ltd. Treatment of ophthalmic conditions with mineralcorticoids
ES2562055T3 (es) * 2005-10-18 2016-03-02 Starpharma Pty Limited Sistema de administración de una composición dendrimérica microbicida
PT1940916T (pt) * 2005-10-25 2017-03-20 Starpharma Pty Ltd Composto macromolecular tendo estequiometria controlada
NZ583333A (en) * 2006-05-31 2011-06-30 Medihoney Pty Ltd Medicinal Compositions Containing Honey
JP5484339B2 (ja) * 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US8802075B2 (en) * 2009-02-18 2014-08-12 Eyeon Particle Sciences Llc Bi-functional co-polymer use for opthalmic and other topical and local applications
US8802654B2 (en) 2009-07-07 2014-08-12 Adenovir Pharma Ab Antiviral compounds
CN103687601B (zh) 2011-05-16 2017-12-08 星法马私人有限公司 治疗或预防细菌性阴道病的方法

Also Published As

Publication number Publication date
EP2895161B1 (en) 2017-05-03
US20190070249A1 (en) 2019-03-07
US20150238557A1 (en) 2015-08-27
JP2015528509A (ja) 2015-09-28
HK1212619A1 (en) 2016-06-17
ES2633778T3 (es) 2017-09-25
US11219691B2 (en) 2022-01-11
US10149885B2 (en) 2018-12-11
JP6766114B2 (ja) 2020-10-07
DK2895161T3 (en) 2017-08-21
CN105007910A (zh) 2015-10-28
CA2884897C (en) 2021-07-27
CA2884897A1 (en) 2014-03-20
JP6419701B2 (ja) 2018-11-07
WO2014043576A1 (en) 2014-03-20
CN105007910B (zh) 2019-03-19
JP2019001827A (ja) 2019-01-10
CN108452316A (zh) 2018-08-28
EP2895161A1 (en) 2015-07-22
EP2895161A4 (en) 2016-03-23
CN108452316B (zh) 2022-04-15

Similar Documents

Publication Publication Date Title
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201201648A1 (ru) Стимуляторы sgc
NZ607600A (en) Compositions for the treatment of diseases
PH12016501204B1 (en) Syk inhibitors
MX349159B (es) Derivados deuterados de ivacaftor.
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ715747A (en) Syk inhibitors
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MY183582A (en) Deuterated cftr potentiators
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX2015008187A (es) Inhibidores de alk deuterados.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201892726A1 (ru) Дейтерированный палбоциклиб
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
SG10201900541QA (en) Derivatives of xanthone compounds
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
MX361642B (es) Composiciones antisépticas catiónicas.